SpyGlass Pharma, Inc. (SGP) — Working Capital to Net Assets Ratio
SpyGlass Pharma, Inc. (SGP) has a Working Capital to Net Assets ratio of 97.7% as of June 2026. Working capital of $227.02 Million (current assets of $236.46 Million minus current liabilities of $9.44 Million) is measured against net assets of $232.36 Million. A higher ratio indicates strong short-term liquidity financed by the equity base. For the complete balance sheet picture, see how large is SpyGlass Pharma, Inc.'s balance sheet.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
SpyGlass Pharma, Inc. Working Capital to Net Assets (2023–2025)
This chart shows how SpyGlass Pharma, Inc.'s Working Capital to Net Assets ratio has evolved across 3 annual periods from 2023 to 2025. As of June 2026, the ratio stands at 97.7%, reflecting working capital of $227.02 Million against net assets of $232.36 Million USD. Explore SGP operating cash flow to total debt to assess how comfortably operating cash covers total debt obligations.
Annual Working Capital to Net Assets for SpyGlass Pharma, Inc. (2023–2025)
The table below presents the year-by-year Working Capital to Net Assets ratio for SpyGlass Pharma, Inc. from 2023 to 2025, covering 3 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. Read SpyGlass Pharma, Inc. total liabilities for a breakdown of total debt and financial obligations.
| Year | WC/NA Ratio | Working Capital (USD) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2025 | -101.4% | $100.18 Million | $-98.84 Million | $108.77 Million | $8.58 Million | ▼ -85.5 pp |
| 2024 | -15.9% | $9.62 Million | $-60.47 Million | $17.41 Million | $7.79 Million | ▲ +102.4 pp |
| 2023 | -118.3% | $39.03 Million | $-32.99 Million | $40.61 Million | $1.59 Million | — |